In HER2-overexpressing patients, these cells also correlated with better clinical responses to immunogenic chemotherapy, suggesting that immunomodulatory therapeutics may provide a novel avenue for the treatment of patients with aggressive forms of breast cancer (23). This evidence concerns the gene ERBB2 and breast carcinoma.